Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 11 03:08PM ET
5.27
Dollar change
+0.12
Percentage change
2.31
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y-53.90% Shs Outstand Perf Week-2.97%
SponsorElevate Shares ETF Type Tagssingle-asset Return% 3Y- Total Holdings14 Perf Month-6.91%
Fund Family Bond Type Tagsoptions Return% 5Y- AUM56.84M Perf Quarter-41.00%
Index- Average Maturity Tagsbiotechnology Return% 10Y NAV% Perf Half Y-71.61%
Index Weighting Commodity Type Tagscovered-call Return% SI NAV/sh Perf Year-73.62%
Active/Passive Quant Type Tags- Flows% 1M132.35% 52W Range4.82 - 26.00 Perf YTD-77.67%
Dividend TTM9.39 (178.20%) ESG Type Tags- Flows% 3M1044.44% 52W High-79.74% Beta0.29
Dividend Ex-DateDec 05, 2024 Dividend Type Sector/Theme Flows% YTD- 52W Low9.31% ATR (14)0.27
Expense0.99% Structure Type Region Flows% 1Y RSI (14)37.35 Volatility5.13% 5.11%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume1.04 Prev Close5.15
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume402.21K Price5.27
SMA20-1.61% SMA50-19.00% SMA200-62.15% Trades Volume365,550 Change2.31%
YieldMax MRNA Option Income Strategy ETF seeks current income; exposure to the share price of the common stock of Moderna, Inc. ("MRNA"), subject to a limit on potential investment gains is the secondary consideration. The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.